Charles Schwab
CTMX icon

Charles Schwab’s CytomX Therapeutics CTMX Stock Holding History

Charles Schwab’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.06M Buy
549,875
+421,079
+327% +$1.61M ﹤0.01% 2780
2026
Q1 		$605K Buy
128,796
+60,109
+88% +$305K ﹤0.01% 3046
2025
Q4 		$293K Sell
68,687
-19,883
-22% -$75.5K ﹤0.01% 3283
2025
Q3 		$283K Hold
88,570
– – ﹤0.01% 3304
2025
Q2 		$201K Buy
88,570
+63,693
+256% +$103K ﹤0.01% 3373
2025
Q1 		$15.8K Buy
24,877
+60
+0.2% +$47 ﹤0.01% 3466
2024
Q4 		$25.6K Hold
24,817
– – ﹤0.01% 3479
2024
Q3 		$29.3K Hold
24,817
– – ﹤0.01% 3464
2024
Q2 		$30.3K Hold
24,817
– – ﹤0.01% 3563
2024
Q1 		$54.1K Hold
24,817
– – ﹤0.01% 3362
2023
Q4 		$38.5K Hold
24,817
– – ﹤0.01% 3428
2023
Q3 		$32K Hold
24,817
– – ﹤0.01% 3456
2023
Q2 		$42.7K Hold
24,817
– – ﹤0.01% 3437
2023
Q1 		$37.5K Sell
24,817
-17,404
-41% -$39.3K ﹤0.01% 3397
2022
Q4 		$67.6K Hold
42,221
– – ﹤0.01% 3307
2022
Q3 		$62K Buy
+42,221
New +$65K ﹤0.01% 3282
2022
Q2 		– Sell
-167,178
Closed -$447K – 3562
2022
Q1 		$447K Buy
167,178
+3,164
+2% +$12.1K ﹤0.01% 3125
2021
Q4 		$711K Sell
164,014
-244
-0.1% -$1.43K ﹤0.01% 3041
2021
Q3 		$837K Sell
164,258
-345,671
-68% -$1.85M ﹤0.01% 2933
2021
Q2 		$3.23M Buy
509,929
+16,420
+3% +$128K ﹤0.01% 2557
2021
Q1 		$3.81M Buy
493,509
+138,866
+39% +$1.1M ﹤0.01% 2426
2020
Q4 		$2.32M Buy
354,643
+31,401
+10% +$224K ﹤0.01% 2550
2020
Q3 		$2.15M Sell
323,242
-4,162
-1% -$30.9K ﹤0.01% 2471
2020
Q2 		$2.73M Buy
327,404
+44,081
+16% +$409K ﹤0.01% 2306
2020
Q1 		$2.17M Buy
283,323
+27,844
+11% +$194K ﹤0.01% 2242
2019
Q4 		$2.12M Sell
255,479
-17,103
-6% -$115K ﹤0.01% 2399
2019
Q3 		$2.01M Buy
272,582
+8,511
+3% +$84K ﹤0.01% 2375
2019
Q2 		$2.96M Sell
264,071
-38,228
-13% -$401K ﹤0.01% 2215
2019
Q1 		$3.25M Buy
302,299
+5,334
+2% +$78.8K ﹤0.01% 2183
2018
Q4 		$4.49M Sell
296,965
-15,454
-5% -$229K ﹤0.01% 1960
2018
Q3 		$5.78M Buy
312,419
+76,493
+32% +$1.74M ﹤0.01% 1968
2018
Q2 		$5.39M Buy
235,926
+37,560
+19% +$959K ﹤0.01% 1955
2018
Q1 		$5.64M Buy
198,366
+21,864
+12% +$624K ﹤0.01% 1874
2017
Q4 		$3.73M Buy
176,502
+8,279
+5% +$172K ﹤0.01% 2067
2017
Q3 		$3.06M Buy
168,223
+50,581
+43% +$789K ﹤0.01% 2117
2017
Q2 		$1.82M Buy
117,642
+17,551
+18% +$265K ﹤0.01% 2248
2017
Q1 		$1.73M Buy
100,091
+4,959
+5% +$65.3K ﹤0.01% 2251
2016
Q4 		$1.05M Buy
95,132
+23,966
+34% +$290K ﹤0.01% 2413
2016
Q3 		$1.12M Buy
71,166
+29,444
+71% +$356K ﹤0.01% 2380
2016
Q2 		$427K Buy
41,722
+18,794
+82% +$214K ﹤0.01% 2643
2016
Q1 		$296K Buy
22,928
+357
+2% +$4.96K ﹤0.01% 2781
2015
Q4 		$472K Buy
+22,571
New +$357K ﹤0.01% 2671

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Charles Schwab's CTMX Position: Q2 2026 in Review

Charles Schwab increased its CytomX Therapeutics (CTMX) stake by 327% in Q2 2026, buying an estimated $1.61M and bringing the position to 549,875 shares worth $2.06M. The position accounts for ﹤0.01% of the portfolio, ranked #2780.

Charles Schwab first reported a position in CTMX in Q4 2015 and has held it in 42 quarters since. The position peaked at $5.78M in Q3 2018. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Charles Schwab held 549,875 shares of CytomX Therapeutics worth $2.06M as of Q2 2026.
  • Charles Schwab bought 421,079 CytomX Therapeutics shares in Q2 2026, an estimated $1.61M.
  • CytomX Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2780 holding.
  • Charles Schwab first reported a position in CytomX Therapeutics in Q4 2015 and has held it in 42 quarters since.
  • Charles Schwab's CytomX Therapeutics position peaked at $5.78M in Q3 2018.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.